L’Oreal Settles With FTC Over Gene-Related Anti-Aging Skin-Care Claims
This article was originally published in The Rose Sheet
Executive Summary
A proposed consent agreement between L’Oreal USA and the Federal Trade Commission bars the company from claiming that skin-care products from its Lancome and L’Oreal Paris brands target users’ genes to award anti-aging benefits. The settlement, which is subject to public comment and final FTC approval, follows a 2012 warning letter from FDA that cited some of the same marketing claims.
You may also be interested in...
Adore Settles With Nationwide Class Over Apple Stem Cell Anti-Aging Claims
The estimated $700,000 settlement puts to rest allegations that the luxury skin-care firm deceived consumers with claims about its PhytoCellTec ingredient’s ability to slow the aging process. G.M. Collin, another PhytoCellTec Malus Domestica user, also appears to have reached a deal with plaintiffs in litigation challenging its anti-aging claims.
Class Action Blight: The Sour Side Of Apple Stem Cell Anti-Aging Boom
Plant stem cell actives such as Mibelle Biochemistry's PhytoCellTec Malus Domestica were marquee ingredients for skin-care brands in the flourishing US anti-aging market years back. But what once was fruitful has turned rotten with regulatory crackdowns in recent years and class actions that continue to weigh on product manufacturers.
Aggressive Claims, FDA Warnings Make Beauty A Bull’s Eye For Litigation
Class-action suits against beauty firms on the rise as industry pushes the envelope with claims and FDA warning letters draw attention from class-action law firms, legal experts note. Hogan Lovells attorney Mark Goodman says: “I don’t see this [trend] going away anytime soon.”